FRAZER, Pa., May 11, 2011 /PRNewswire/ -- Today, Cephalon,
Inc. (NASDAQ: CEPH) recognizes those who stay awake to keep our
society moving while the rest of us are sleeping by honoring
National Night Shift Workers Day and introducing a new video,
"Shift Your Assumptions," as a tribute to shift workers.
According to the U.S. Department of Labor, over 15 million
Americans work odd hours or non-traditional shifts and may be at
risk for a medical condition called shift work disorder, in which
their body's clock is out of sync with their work schedule. As part
of The Wake-Up Squad(SM), a national disease awareness initiative
developed by Cephalon to educate community members about health
concerns related to shift work disorder, the Company encourages the
public to recognize those who work non-traditional hours by
thanking a shift worker and sharing with family and friends the new
two-minute video, "Shift Your Assumptions." To access the
video and learn more about shift work disorder visit
www.TheWakeUpSquad.com.
Up to 25 percent of people who work night or rotating-shifts are
estimated to have shift work disorder, a medical condition in which
the body's internal sleep-wake clock is out of sync with the
individual's work schedule—their body is telling them to go to
sleep when their work schedule needs them to stay awake. Because of
this disruption of the body's natural rhythm, people with shift
work disorder often struggle to stay awake during their waking
hours (excessive sleepiness), or have trouble sleeping during their
sleeping hours (insomnia).
About The Wake-Up Squad
The Wake-Up Squad is an award-winning educational program
designed to motivate and mobilize community members about shift
work disorder. The website features information about shift
work disorder and provides tools, such as a symptom checklist, to
help prepare for a discussion with a healthcare professional.
In addition, Community Educators trained to talk about shift
work disorder are in various cities and communities across the
country. To learn more about shift work disorder or to
register to take a self-assessment, visit
www.TheWakeUpSquad.com.
About Cephalon, Inc.
Cephalon is a global biopharmaceutical company dedicated to
discovering, developing and bringing to market medications to
improve the quality of life of individuals around the world.
Since its inception in 1987, Cephalon has brought
first-in-class and best-in-class medicines to patients in several
therapeutic areas. Cephalon has the distinction of being one
of the world's fastest-growing biopharmaceutical companies, now
among the Fortune 1000 and a member of the S&P 500 Index,
employing approximately 4,000 people worldwide. The company
sells numerous branded and generic products around the world.
In total, Cephalon sells more than 150 products in nearly 100
countries. More information on Cephalon and its products is
available at www.cephalon.com.
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide the Cephalon current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs; development of potential pharmaceutical
products; interpretation of clinical results; prospects for
regulatory approval; manufacturing development and capabilities;
market prospects for its products; and other statements regarding
matters that are not historical facts. You may identify some
of these forward-looking statements by the use of words in the
statements such as "anticipate," "estimate," "expect," "project,"
"intend," "plan," "believe" or other words and terms of similar
meaning. Cephalon performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, regulatory and political
conditions affecting the biotechnology and pharmaceutical
industries as well as more specific risks and uncertainties facing
Cephalon such as those set forth in its reports on Form 8-K, 10-Q
and 10-K filed with the U.S. Securities and Exchange Commission.
Given these risks and uncertainties, any or all of these
forward-looking statements may prove to be incorrect. Therefore,
you should not rely on any such factors or forward-looking
statements. Furthermore, Cephalon does not intend to update
publicly any forward-looking statement, except as required by law.
The Private Securities Litigation Reform Act of 1995 permits this
discussion.
Contacts:
Media:
Jenifer Antonacci
610-738-6674 (office)
jantonacci@cephalon.com
Investor Relations:
Chip Merritt
610-738-6376 (office)
cmerritt@cephalon.com
Joseph Marczely
610-883-5894 (office)
jmarczely@cephalon.com
SOURCE Cephalon, Inc.